INSUBCONTINENT EXCLUSIVE:
With skyrocketing demand for consumer products and renewed research into its medicinal value, cannabis is having a moment.The
quasi-legalization of marijuana created a gold rush for the industry, and startups like Demetrix are reaping the benefits.The company,
Berkeley researcher Jay Keasling and helmed by former Amyris executive Jeff Ubersax just raised $50 million in a new round of financing to
continue its pursuit of isolating and brewing cannabinoids, the active chemical ingredients in the marijuana plant.The money came from
previous investor Horizons Ventures, the Hong Kong-based firm backed by real estate billionaire Li Ka-shing, and Tuatara Capital, a fund
The technology Keasling developed gives the company a unique ability to isolate and develop new cannabinoids and start screening them for
cheaper to just extract from the plant itself cannabinoids used in existing products, as the body of research grows around applications for
the more rare cannabinoids found in smaller percentages in the plant itself, brewing the active chemicals will start to look more and more
appealing.Demetrix says it will use the money from the new financing to scale its operations and commercialize the first of the more than
